Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 11 patents granted in the last 365 days
Sunshine Lake Pharma Co., Ltd. maintains a portfolio in the Biotechnology & Pharmaceuticals technology area. There are currently 6 pending office actions. These actions are distributed across 6 distinct examiners and 5 distinct art units, which reflects a high degree of diversity in the company's active prosecution.
CONIGLIO, AUDREA JUNE BUCKLEY is the busiest examiner for this portfolio, with 1 busiest examiner pending office action. Because there are 6 pending office actions and 6 distinct examiners, each examiner is responsible for a single action. The involvement of 5 distinct art units indicates that the pending applications are spread across nearly as many technical divisions as there are actions.
For practitioners, this data shows that the company's current biotechnology filings are facing independent reviews. With 6 distinct examiners and 5 distinct art units, there is no single individual or technical group dominating the workload. The outcome for the company depends on the 1 busiest examiner pending action and the other independent cases.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (17%) |
| §112 only | 2 (33%) |
| Multi-statute (no §101) | 3 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CONIGLIO, AUDREA JUNE BUCKLEY | 1 | 52.9% | +21.1% |
| YOO, SUN JAE | 1 | 71.1% | +0.3% |
| DABKOWSKI, ERINNE R | 1 | 55.9% | +69.0% |
| RODRIGUEZ, RAYNA B | 1 | 33.6% | +19.2% |
| LEE, HOI YAN NMN | 1 | 38.4% | +75.9% |
| WILSON, JERICA KATLYNN | 1 | 61.4% | +39.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18699131 | ANTIFIBROTIC COMPOSITION | CONIGLIO, AUDREA JUNE BUCKLEY | — |
| 18697795 | NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | YOO, SUN JAE | — |
| 18563090 | A NOVEL ACYLATED INSULIN ANALOG | DABKOWSKI, ERINNE R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18013619 | SALT OF 2-(SUBSTITUTED PYRIMIDINYL) THIAZOLE CARBOXAMIDE COMPOUND, AND COMPOSITION AND USE THEREOF | WILSON, JERICA KATLYNN | 155d overdue |
| 18015138 | METHOD FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND INTERMEDIATES THEREOF | LEE, HOI YAN NMN | 34d |
| 18699131 | ANTIFIBROTIC COMPOSITION | CONIGLIO, AUDREA JUNE BUCKLEY | — |
| 18563090 | A NOVEL ACYLATED INSULIN ANALOG | DABKOWSKI, ERINNE R | — |
| 18285136 | CRYSTALLINE FORM OF PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | RODRIGUEZ, RAYNA B | — |
| Art Unit | Apps |
|---|---|
| 1621 | 2 |
| 1617 | 1 |
| 1654 | 1 |
| 1628 | 1 |
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18699131 | ANTIFIBROTIC COMPOSITION | CONIGLIO, AUDREA JUNE BUCKLEY | 1617 | §103§112 | Non-Final OA | — | Pending | Apr 05, 2024 |
| 18697795 | NOVEL PYRIMIDOPYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | YOO, SUN JAE | 1621 | §102§112 | Non-Final OA | — | Pending | Apr 02, 2024 |
| 18563090 | A NOVEL ACYLATED INSULIN ANALOG | DABKOWSKI, ERINNE R | 1654 | §103§112 | Non-Final OA | — | Pending | Nov 21, 2023 |
| 18285136 | CRYSTALLINE FORM OF PYRROLE AMIDE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | RODRIGUEZ, RAYNA B | 1628 | §112 | Final Rejection | — | Pending | Sep 29, 2023 |
| 18015138 | METHOD FOR PREPARING GLUCOPYRANOSYL DERIVATIVES AND INTERMEDIATES THEREOF | LEE, HOI YAN NMN | 1693 | §103 | Non-Final OA | 34d | Pending | Jan 09, 2023 |
| 18013619 | SALT OF 2-(SUBSTITUTED PYRIMIDINYL) THIAZOLE CARBOXAMIDE COMPOUND, AND COMPOSITION AND USE THEREOF | WILSON, JERICA KATLYNN | 1621 | §112 | Non-Final OA | 155d overdue | Pending | Dec 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial